Press release
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"\nEntered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $200 million upfront and up to $4.3 billion in potential development and commercial milestones\n\nBARDA award announced for up to $63.2 million to support development of a self-amplifying mRNA vaccine for rapid pandemic influenza response\n\nNew LUNAR-CF preclinical data demonstrates effective delivery of ARCT-032 with LUNAR®, resulting in functional restoration of chloride ion current in CF subject bronchial epithelial cells\n\nInvestor conference call at 4:30 p.m. EST today\n\n SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2022, and provided corporate updates.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109006003/en/Figure: Bronchial epithelial cells (BECs) obtained from human CF donors were treated with ARCT-032 and demonstrated robust restoration of CFTR activity (chloride ion current) vs. control BECs obtained from human non-CF donors. (Graphic: Business Wire)\n\"Arcturus continues to execute on the promise of our next-generation self-amplifying mRNA vaccine franchise through engagements with CSL and BARDA,\" said Joseph Payne, President and CEO of Arcturus Therapeutics. \"These new partnerships expand the scope of our technology while providing substantial capital to accelerate the development of our vaccine and therapeutic programs. In addition, promising new data from ARCT-032, our CF therapeutic candidate, was recently featured at the North American Cystic Fibrosis Conference and we expect to file a CTA before year end.\"\n\nRecent Corporate Highlights\n\n\nAnnounced a strategic collaboration with CSL Seqirus, one of the top two global influenza vaccine companies, for the development, manufacture, and commercialization of mRNA-based vaccines. Arcturus will receive $200 million upfront, up to $4.3 billion in potentia...